Patents Assigned to Eberhard Karls Universitaet Tuebingen Medizinische Fakultaet
-
Publication number: 20240400978Abstract: The present invention relates to a method for producing biocompatible structures for the connection and cultivation of biological material, a method for cultivating aggregates of biological material, and the use of biocompatible structures for the connection and cultivation of biological material.Type: ApplicationFiled: June 4, 2024Publication date: December 5, 2024Applicant: EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAETInventors: Kevin ACHBERGER, Stefan LIEBAU
-
Publication number: 20240122882Abstract: The invention is directed to a compound for use in the prophylaxis and/or treatment of leukemia and/or the development of leukemia, a pharmaceutical composition for the prophylaxis and/or treatment of leukemia and/or the development of leukemia, comprising said compound, a method for the prophylaxis and/or treatment of leukemia and/or the development of leukemia in a living being, a single guide RNA (sgRNA) molecule which can be used in the method according to the invention.Type: ApplicationFiled: October 18, 2023Publication date: April 18, 2024Applicant: EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAETInventors: Julia SKOKOWA, Benjamin DANNENMANN, Maksim KLIMIANKOU
-
Publication number: 20230165510Abstract: The present invention relates to an apparatus for the treatment of an epilepsy-associated disorder in a living being and to a method for the treatment of an epilepsy-associated disorder in a living being.Type: ApplicationFiled: January 26, 2023Publication date: June 1, 2023Applicant: Eberhard Karls Universitaet Tuebingen Medizinische FakultaetInventors: Jens KLINZING, Hong-Viet Victor NGO
-
Patent number: 11591568Abstract: The present invention relates to myeloid-derived suppressor cells (MDSC) and exosomes derived therefrom (MDSC exo) and application thereof.Type: GrantFiled: June 4, 2019Date of Patent: February 28, 2023Assignee: Eberhard Karls Universitaet Tuebingen Medizinische FakultaetInventors: Natascha Koestlin, Christian Gille
-
Publication number: 20220280526Abstract: The present invention relates to the use of EZH2 inhibitors for the treatment of psoriasis, a pharmaceutical composition for the treatment of psoriasis comprising said EZH2 inhibitors, a method for the preparation of said pharmaceutical composition, a method for the therapeutic treatment of a living being against psoriasis, a method for the screening of active agents against psoriasis, and the use in vitro of a EZH2 inhibitor for the suppression of the cellular I?B? expression.Type: ApplicationFiled: March 29, 2022Publication date: September 8, 2022Applicant: EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAETInventors: Daniela KRAMER, Anne MUELLER, Klaus SCHULZE OSTHOFF
-
Publication number: 20220280511Abstract: The present invention relates to the use of CDK4/6 inhibitors for the treatment of psoriasis, a pharmaceutical composition for the treatment of psoriasis comprising said CDK4/6 inhibitors, a method for the preparation of said pharmaceutical composition, a method for the therapeutic treatment of a living being against psoriasis, a method for the screening of active agents against psoriasis, and the use in vitro of a CDK4/6 inhibitor for the suppression of the cellular I?B? expression.Type: ApplicationFiled: March 29, 2022Publication date: September 8, 2022Applicant: EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAETInventors: Daniela KRAMER, Anne MUELLER, Klaus SCHULZE OSTHOFF
-
Publication number: 20220249346Abstract: The invention relates to a polyribonucleotide, a cosmetic and pharmaceutical compound that has the polyribonucleotide and a medicinal product that has the polyribonucleotide and the compound.Type: ApplicationFiled: October 5, 2021Publication date: August 11, 2022Applicant: Eberhard Karls Universitaet Tuebingen Medizinische FakultaetInventors: Hans-Peter WENDEL, Timea KELLER, Andrea NOLTE, Meltem AVCI-ADALI, Tobias WALKER
-
Publication number: 20220153816Abstract: The present invention relates to a cytotoxic agent for the prophylaxis and/or treatment of a viral infection which is configured for the selective binding to a membrane receptor of virus-infected T lymphocytes, a pharmaceutical composition containing said cytotoxic agent, the use of the cytotoxic agent for the prophylaxis and/or treatment of viral infections, a method of finding cytotoxic agents, the use of a membrane receptor of virus-infected T lymphocytes which is overexpressed in comparison to non-infected T lymphocytes for the diagnosis of a viral infection.Type: ApplicationFiled: December 2, 2021Publication date: May 19, 2022Applicant: Eberhard Karls Universitaet Tuebingen Medizinische FakultaetInventors: Michael Schindler, Marius Codrea, Sven Nahnsen, Herwig Koppensteiner, Gundram JUNG, Martin HOFMANN
-
Patent number: 11332726Abstract: The present invention relates to a nucleotide-modified messenger RNA for the permanent correction of a genetic alteration on a DNA. The invention further relates to a nucleotide-modified messenger RNA in combination with a repair template. It also relates to a pharmaceutical composition. It finally relates to methods for the correction of a genetic alteration on a DNA.Type: GrantFiled: April 30, 2019Date of Patent: May 17, 2022Assignees: EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄT, HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH FÜR DAS HELMHOLTZ-INSTITUT FÜR PHARMAZEUTISCHE FORSCHUNG SAARLAND (HIPS)Inventors: Michael Kormann, Lauren Mays Weddle, Claus-Michael Lehr, Brigitta Loretz, Emad Malaeksefat
-
Publication number: 20220098677Abstract: The present invention relates to a method for determining in a subject's biological sample the relative proportions of papillary renal cell carcinoma (pRCC), clear cell renal cell carcinoma (ccRCC), and chromophobe renal cell carcinoma (chRCC), an array comprising capture molecules capable of specifically binding to RCC signature genes or coding sequences thereof or products encoded thereby, and the use of RCC signature genes for classifying a subject into a renal cell carcinoma (RCC) risk group and/or for determining in a subject's biological sample the relative proportions of pRCC, ccRCC, and chRCC.Type: ApplicationFiled: October 7, 2021Publication date: March 31, 2022Applicants: Robert Bosch Gesellschaft für medizinische Forschung mbH, Eberhard Karls Universität Tuebingen Medizinische Fakultaet, Friedrich-Alexander-Universitaet Erlangen-NuernbergInventors: Florian Buettner, Elke Schaeffeler, Matthias Schwab, Stefan Winter, Jens Bedke, Arnulf Stenzl, Arndt Hartmann
-
Patent number: 11286500Abstract: A nucleic acid molecule can code for an Orf virus vector promoter. A recombinant Orf virus vector can be included in a cell. The nucleic acid molecule, the vector and/or the cell can be included in a composition. The recombinant Orf virus vector can be used for the production of a foreign gene.Type: GrantFiled: January 19, 2018Date of Patent: March 29, 2022Assignee: EBERHARD KARLS UNIVERSITÄT TÜBINGEN MEDIZINISCHE FAKULTÄTInventors: Hanns-Joachim Rziha, Ralf Amann
-
Patent number: 11229651Abstract: The present invention relates to substances for the prophylaxis and treatment of a neurodegenerative disease which is not based on a protein-folding disorder. It further relates to substances for the stabilization of photoreceptors.Type: GrantFiled: March 28, 2016Date of Patent: January 25, 2022Assignee: Eberhard Karls Universitaet Tuebingen Medizinische FakultaetInventors: Marius Ueffing, Blanca Arango-Gonzalez, Ana Griciuc
-
Publication number: 20220016219Abstract: The present application relates to a pharmaceutical composition for use in a method of treating diabetes in a human or animal subject in need thereof, to transplantation devices comprising the pharmaceutical composition of the present invention and to methods of treating diabetes using the pharmaceutical composition and transplantation device of the present invention.Type: ApplicationFiled: July 28, 2021Publication date: January 20, 2022Applicant: Eberhard Karls Universitaet Tuebingen Medizinische FakultaetInventors: Shannon Layland, Katja Schenke-Layland, Garry Duffy, Svenja Hinderer, Aline Zbinden
-
Patent number: 11208469Abstract: The present invention relates to a cytotoxic agent for the prophylaxis and/or treatment of a viral infection which is configured for the selective binding to a membrane receptor of virus-infected T lymphocytes, a pharmaceutical composition containing said cytotoxic agent, the use of the cytotoxic agent for the prophylaxis and/or treatment of viral infections, a method of finding cytotoxic agents, the use of a membrane receptor of virus-infected T lymphocytes which is overexpressed in comparison to non-infected T lymphocytes for the diagnosis of a viral infection.Type: GrantFiled: September 14, 2018Date of Patent: December 28, 2021Assignee: EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAETInventors: Michael Schindler, Marius Codrea, Sven Nahnsen, Herwig Koppensteiner, Gundram Jung, Martin Hofmann
-
Patent number: 11058777Abstract: The present invention relates to a nucleic acid molecule which encodes a splice variant of the human P2RX7 receptor, and nucleic acid molecules derived therefrom, a recombinant vector containing said nucleic acid molecules, a host containing said recombinant vector, a polypeptide encoded by said nucleic acid molecules, a host cell expressing said polypeptide, a binding molecule binding to said polypeptide, a pharmaceutical composition comprising said binding molecule, a method for the production of the isolated polypeptide, and other methods and uses in connection therewith.Type: GrantFiled: May 17, 2018Date of Patent: July 13, 2021Assignees: EBERHARD KARLS UNIVERSITÄT TUEBINGEN MEDIZINISCHE FAKULTAET, DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTSInventors: Jens Gesche, Sorin Armeanu-Ebinger, Guido Seitz, Harald Surowy
-
Patent number: 10898454Abstract: A composition for the prophylaxis and/or treatment of a developmental disorder which is associated with preterm birth, and a method for the diagnosis and/or determination and/or prediction of the degree of severity of a developmental disorder which is associated with preterm birth.Type: GrantFiled: July 28, 2017Date of Patent: January 26, 2021Assignee: EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAETInventors: Wolfgang Bernhard, Axel Franz
-
Patent number: 10759752Abstract: The present invention relates to a composition for the modulation of the activity of non-structure proteins and a compound contained therein.Type: GrantFiled: January 30, 2019Date of Patent: September 1, 2020Assignee: Eberhard Karls Universitaet Tuebingen Medizinische FakultaetInventors: Bernhard Hirt, Claus Zeyher, Corinna Gleiser, Lothar Just
-
Patent number: 10616699Abstract: In a hearing aid (26) that can be inserted into the ear canal (12) of a patient, comprising an actuator (31) effecting a mechanical stimulation of the tympanic membrane (14), the actuator (31) comprises an inner surface (32) associated with the tympanic membrane (14) and an outer surface (42) associated with the ear canal (12) and is configured as an areal disk actuator, whose deformation stimulates the tympanic membrane (14) by areal deformation. On the actuator (31) at a distance from the outer surface (42) a cover plate (43) is arranged which together with the outer surface (42) delimits a preferably lenticular cavity (48).Type: GrantFiled: January 17, 2019Date of Patent: April 7, 2020Assignee: EBERHARD KARLS UNIVERSITAET TUEBINGEN MEDIZINISCHE FAKULTAET GESCHWISTER-SCHOLL-PLATZInventors: Ernst Dalhoff, Hans-Peter Zenner
-
Publication number: 20190381198Abstract: The present invention relates to novel compounds useful for visualizing cell senescence in vitro and in vivo, the preparation of said compounds and their use. In particular, the present invention pertains to novel hexose and particularly galactose derivatives which are useful as senescence tracers in vitro and in vivo.Type: ApplicationFiled: August 21, 2019Publication date: December 19, 2019Applicant: Eberhard Karls Universitaet Tuebingen Medizinische FakultaetInventors: Jonathan Cotton, Anna Kuehn, Andreas Maurer, Bernd Pichler, Klaus Schulze-Osthoff, Kerstin Fuchs, Marcel André Krueger, Lars Zender
-
Publication number: 20190376051Abstract: The present invention relates to a nucleotide-modified messenger RNA for the permanent correction of a genetic alteration on a DNA. The invention further relates to a nucleotide-modified messenger RNA in combination with a repair template. It also relates to a pharmaceutical composition. It finally relates to methods for the correction of a genetic alteration on a DNA.Type: ApplicationFiled: April 30, 2019Publication date: December 12, 2019Applicants: Eberhard Karls Universität Tübingen Medizinische Fakultät, Helmholtz-Zentrum für Infektionsforschung GmbH für das Helmholtz-Institut für PharmazeutischeInventors: Michael KORMANN, Lauren Mays WEDDLE, Claus-Michael LEHR, Brigitta LORETZ, Emad MALAEKSEFAT